Related Experiment Video

Updated: Jul 19, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

779

The HEARTS partner forum-supporting implementation of HEARTS to treat and control hypertension

Taskeen Khan1, Andrew E Moran2,3, Pablo Perel4,5

  • 1Department of Non-communicable Diseases, World Health Organization, Geneva, Switzerland.

Frontiers in Public Health
|August 9, 2023
PubMed

Insights

The Global HEARTS initiative, led by WHO and CDC, addresses cardiovascular diseases (CVD) and hypertension through primary healthcare. This public health approach has successfully treated over seven million people for hypertension, demonstrating its feasibility and role in universal health coverage.

Area of Science:

  • Public Health
  • Cardiovascular Medicine
  • Global Health Initiatives

Background:

  • Cardiovascular diseases (CVD), including ischemic heart disease (IHD) and stroke, are the leading global causes of death and disability.
  • High blood pressure is the most significant preventable risk factor for CVD, contributing to millions of deaths annually.
  • The Global HEARTS initiative was launched by WHO and CDC to support countries in preventing and controlling CVD.

Purpose of the Study:

  • To outline the HEARTS technical package and its public health approach to managing hypertension and CVD risk factors at the primary healthcare level.
  • To highlight the role of the HEARTS Partner Forum in coordinating 11 international organizations to support country-level CVD prevention efforts.
  • To demonstrate the feasibility and acceptability of the HEARTS approach and its potential as a pathway to universal health coverage.

Main Methods:

  • Implementing the HEARTS technical package, a core component of the Global HEARTS initiative, at the primary healthcare level.
  • Utilizing a simple, algorithmic approach for hypertension treatment.
  • Facilitating collaboration and support through the HEARTS Partner Forum, involving multiple international organizations.

Main Results:

  • Over seven million individuals have been treated for hypertension using the HEARTS approach.
  • The HEARTS initiative has demonstrated the feasibility and acceptability of a public health strategy for CVD risk factor management.
  • Hypertension management through HEARTS shows potential as a key intervention for achieving universal health coverage.

Conclusions:

  • The HEARTS Partner Forum is crucial for advancing CVD prevention and control globally.
  • A more structured approach for the forum, including clear goals and reports, is needed to enhance collaboration and impact.
  • The HEARTS initiative contributes to reducing CVD mortality and achieving Sustainable Development Goals (SDGs).

Keywords:
cardiovascular diseasesglobal healthhealth systemshypertensionimplementationpartnershipsprimary healthcareuniversal health coverage

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Hypertension I: Introduction01:28

Hypertension I: Introduction

Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
16